PMID- 30379598
OWN - NLM
STAT- MEDLINE
DCOM- 20191209
LR  - 20191217
IS  - 1545-326X (Electronic)
IS  - 0066-4219 (Linking)
VI  - 70
DP  - 2019 Jan 27
TI  - Redirected T Cell Cytotoxicity in Cancer Therapy.
PG  - 437-450
LID - 10.1146/annurev-med-062617-035821 [doi]
AB  - Bispecific antibodies that recruit and redirect T cells to attack tumor cells 
      have tremendous potential for the treatment of various malignancies. In general, 
      this class of therapeutics, known as CD3 bispecifics, promotes tumor cell killing 
      by cross-linking a CD3 component of the T cell receptor complex with a 
      tumor-associated antigen on the surface of the target cell. Importantly, this 
      mechanism does not rely on a cognate interaction between the T cell receptor and 
      a peptide:HLA complex, thereby circumventing HLA (human leukocyte antigen) 
      restriction. Hence, CD3 bispecifics may find a key role in addressing tumors with 
      low neoantigen content and/or low inflammation, and this class of therapeutics 
      may productively combine with checkpoint blockade. A wide array of formats and 
      optimization approaches has been developed, and a wave of CD3 bispecifics is 
      proceeding into human clinical trials for a range of indications, with promising 
      signs of therapeutic activity.
FAU - Clynes, Raphael A
AU  - Clynes RA
AD  - Xencor, Inc., Monrovia, California 91016, USA; email: rclynes@xencor.com , 
      jrd@xencor.com.
FAU - Desjarlais, John R
AU  - Desjarlais JR
AD  - Xencor, Inc., Monrovia, California 91016, USA; email: rclynes@xencor.com , 
      jrd@xencor.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181031
PL  - United States
TA  - Annu Rev Med
JT  - Annual review of medicine
JID - 2985151R
RN  - 0 (Antibodies, Bispecific)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CD3 Complex)
SB  - IM
MH  - Animals
MH  - Antibodies, Bispecific/*therapeutic use
MH  - Antigens, Neoplasm/*immunology
MH  - CD3 Complex/*administration & dosage/immunology
MH  - Cytotoxicity, Immunologic/drug effects/immunology
MH  - Forecasting
MH  - Humans
MH  - Immunotherapy/*methods/trends
MH  - Neoplasms/immunology/*therapy
MH  - Risk Assessment
MH  - T-Lymphocytes/drug effects/*immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CD3 bispecific
OT  - Fc domain
OT  - PD-1 blockade
OT  - antibody
OT  - cytokine release syndrome
EDAT- 2018/11/01 06:00
MHDA- 2019/12/18 06:00
CRDT- 2018/11/01 06:00
PHST- 2018/11/01 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2018/11/01 06:00 [entrez]
AID - 10.1146/annurev-med-062617-035821 [doi]
PST - ppublish
SO  - Annu Rev Med. 2019 Jan 27;70:437-450. doi: 10.1146/annurev-med-062617-035821. 
      Epub 2018 Oct 31.